Sanofi, GlaxoSmithKline signs deal with Canada to deliver 72 million doses of potential COVID-19 vaccine

/ / News

Sanofi and GlaxoSmithKline PLC announced Tuesday that the companies have signed agreements with Canada to supply up to 72 million doses of their COVID-19 vaccine, starting in 2021. The companies had initiated a Phase 1/2 study on their vaccine candidate on Sept. 3, and expect first results in early December to support the initiation of a Phase 3 study before the end of the year. The companies said if the data is sufficient, they plan to request regulatory approval in the first half of 2021. “To address a global health crisis of this magnitude, it takes partnerships and we are grateful to Canada for its collaboration, and to [GlaxoSmithKline] for partnering with us to develop a safe and effective vaccine,” said Thomas Triomphe, global head of Sanofi Pasteur. Separately, Moderna Inc. said Canada has increased its order commitment to 20 million doses of the company’s COVID-19 vaccine candidate, mRNA-1273. Moderna said its Phase 3 study has enrolled more than 75% of its participants. Shares of Sanofi have slipped 0.9% year to date, GlaxoSmithKline’s stock has dropped 19.7% and Moderna’s stock has soared 248.7%, while the S&P 500 has gained 1.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.